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Background: High incidences of neck pain morbidity are challenging in various situations for populations based on their
demographic, physiological and pathological characteristics. Chinese proprietary herbal medicines, as Complementary
and Alternative Medicine (CAM) products, are usually developed from well-established and long-standing recipes
formulated as tablets or capsules. However, good quantification and strict standardization are still needed for
implementation of individualized therapies. The Qishe pill was developed and has been used clinically since 2009. The
Qishe pill’s personalized medicine should be documented and administered to various patients according to the ancient
TCM system, a classification of personalized constitution types, established to determine predisposition and prognosis to
diseases as well as therapy and life-style administration. Therefore, we describe the population pharmacokinetic profile of
the Qishe pill and compare its metabolic rate in the three major constitution types (Qi-Deficiency, Yin-Deficiency and
Blood-Stasis) to address major challenges to individualized standardized TCM.
Methods/Design: Healthy subjects (N = 108) selected based on constitutional types will be assessed, and standardized
pharmacokinetic protocol will be used for assessing demographic, physiological, and pathological data. Laboratory
biomarkers will be evaluated and blood samples collected for pharmacokinetics(PK) analysis and second-generation
gene sequencing. In single-dose administrations, subjects in each constitutional type cohort (N = 36) will be randomly
divided into three groups to receive different Qishe pill doses (3.75, 7.5 and 15 grams).
Multiomics, including next generation sequencing, metabolomics, and proteomics, will complement the Qishe pill’s
multilevel assessment, with cytochrome P450 genes as targets. In a comparison with the general population, a
systematic population pharmacokinetic (PopPK) model for the Qishe pill will be established and verified.
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Neck pain is one of the most common symptoms of
cervical spine disease. Many treatments are available to
patients and considered standard in clinical practice.
They include common conservative strategies such as
medication, physical methods, manual treatments, and
education of patients. However, current evidence for the
management of neck pain reveals that conservative
interventions, especially Chinese herbal medicine, have
not been studied in enough detail to assess their efficacy
or effectiveness adequately [1]. Possible reasons for the
failure of current clinical practice to effectively manage
neck pain lie in two main domains: first, the most
difficult challenge faced is clinical heterogeneity, which
appears at many levels, such as in the sample group,
type of herbal medicine used and outcomes measured
[2]; and second, although Chinese proprietary herbal
medicines are usually based on well-established and
long-standing recipes and formulated as tablets or capsules
for commerce, convenience and/or palatability, good
quantification and strict detailed standardization still
need to be improved.
As individualized diagnostic and therapeutic strategies
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come and assessing risk, which make individualized pre-
vention and early intervention strategies conceivable and
practicable. According to the ancient TCM system, a clas-
sification of individualized constitution types has been
established to determine predisposition and prognosis to
diseases as well as therapy and life-style administration
[3]. An official Classification and Determination of TCM
Constitution [4] was released by the State Administration
of TCM and the constitution branch of the Chinese
Medical Association in April, 2009. Meanwhile, a stan-
dardized scale called Constitution in Chinese Medicine
Questionnaire (CCMQ) [5-7] was designed based on the
above classification. However, its reliability and validity
has not been verified with comprehensive, large sample
size trials. In the clinic, it takes a lot of practice for TCM
specialists to be really efficient at adopting the four
TCM examinations (observation, listening and smelling,
inquiring, feeling the pulse and palpation) to totally assess
the participants and determine their constitutional types
based on physical, mental, physiological, and pathological
attributes, which are called Ti Zhi. There are nine kinds of
broad constitutional types with a varying degree of predis-
position to different diseases (Table 1). Among these, themedicine (TCM) constitutional types [3,13,14]
hological
cteristics
Sign of health Sign of illness
character Good cold and hot tolerance,
sleep well, good appetite and
no fatigue
Less disease
esire to speak Short of breath, listless and






Intolerance of cold, loose
stool, clear abundant urine
and easy to catch a cold
Diarrhea
-tempered Feverish palms and soles,
dry mouth and throat,
dry eyes, flushing cheek,




nt Feeling body heaviness,
chest distress and excessive
phlegm, sticky mouth, and
sticky sweating in usual
Stroke and Diabetes
to be irritable likely to suffer from acne,
thirsty, bad breath, bitter












and pain in chest
hypochondria
pes Hypersensitiveness Asthma and urticaria
have been selected in this trial.
Sun et al. Trials  (2015) 16:64 Page 3 of 10three most contrasting constitutional types, Qi-Deficiency,
Yin-Deficiency and Blood-Stasis, are the most vulnerable
to chronic musculoskeletal diseases [3]. In the realm of
modern predictive medicine, efforts are being directed
toward capturing disease phenotypes with greater precision
for successful identification of markers for prospective
disease conditions.
In the early 1990s, the YQHYTL formula was proposed
for neck pain and subsequently underwent further investi-
gation to establish the medicine’s efficacy. Based on the
YQHYTL formula, the Qishe pill (Shanghai Sundise
Traditional Chinese Medicine Co., Ltd, China), which
is composed of processed Radix Astragali, Muscone,
Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae,
Caulis Sinomenii, and Calculus Bovis Artifactus (Table 2),
was developed and has been widely used in clinical
settings since 2009 [8-11]. The Qishe pill is a thin 0.15 g
film-coated pill with a slightly penetrating odor and a
mildly bitter flavor. Production and processing of the
Qishe pill are described as follows: (1) the volatile oil is
extracted from Szechuan Lovage Rhizome on standby; (2)
the remaining drug decoction from Szechuan Lovage
Rhizome is mixed with Radix Astragali, which has been
soaked for 30 min, and simmered in 10 volumes of water,
twice, for 2 hours each time; (3) the decoction is then vac-
uum filtrated to a relative density of 1.24 to 1.26 (70°C),
and ethanol is added to the concentrated decoction
to bring to a 70% alcohol content; (4) after filtration
and concentration (ethanol recovery), the remaining
sample is vacuum dried and then crushed into a fine
powder; (5) from this mixture, which contains 14 volumes
of 70% ethanol, Radix Stephaniae Tetrandrae and Caulis
Sinomenii are extracted with the circumfluent alcohol,
three times for 2 hours, concentrated with recovery of
ethanol, vacuum dried again, and crushed into a fine
powder; (6) the volatile oil of Szechuan Lovage Rhizome is
then mixed with four parts β-cyclodextrin and dried
under vacuum; and (7) the porphyrized powder of the
Calculus Bovis Artifactus and Muscone are mixed with the
β-cyclodextrin and the other two fine powders mentioned
above, pelleted and coated, to obtain the pills called the
Qishe pill (drug name).Table 2 Standard formula (capsule ingredients)*
Chinese Name Pharmaceutical Name Powered Herb, %
Huang Qi Radix Astragali 28% (13g)
She Xiang Muscone 0. (0.03g)
Chuan Xiong Szechuan Lovage Rhizome 26% (12g)
Fang Ji Radix Stephaniae Tetrandrae 19% (9g)
Qing Feng Teng Caulis Sinomenii 26% (12g)
Niu Huang Calculus Bovis Artifactus 0. (0.3g)
*Pharmaceutical terminology from Hsu [12].With the high incidence of neck pain morbidity
[13-16], and the wide variety of population properties
(age, gender, weight, constitutional type, history of disease
and life style, etc.) involved, providing an individual
patient with optimal treatment at a given time is challen-
ging. Therefore, personalized administration of the Qishe
pill should be documented and practiced with multiple
patients. Thus, a comprehensive research concerning the
population pharmacokinetics (PopPK) of the Qishe pill in
Chinese subjects should be conducted. In this study, we
describe the population pharmacokinetic profile of the
Qishe pill and compare its extent of metabolism in the three
major constitution types (Qi-Deficiency, Yin-Deficiency and
Blood-Stasis) to address major challenges of individualized
and standardized Traditional Chinese Medicine into clinical
practice, as a pilot trial.Methods/Design
Study design
This single-center, three cohort, open-label, double-
Latin-sequence, crossover study will be conducted in
108 healthy adult subjects (36 subjects in each co-
hort) who meet the inclusion and exclusion criteria.
The experiments will be conducted in accordance
with good clinical practice procedures, all applicable
regulatory requirements, and the guiding principles
of the Declaration of Helsinki. This study was ap-
proved by the ethics committee of the institutional
review board in Longhua Hospital, Shanghai Univer-
sity of TCM (2013-LCSY-064). After completing
baseline description of the study to the enrolled sub-
jects, written informed consent will be obtained from
each of them.
The sample size was established according to GCP
guidelines of SFDA, which recommend 8 to 12 subjects
in a clinical pharmacokinetic trial. The study will take
place at the phase I unit of Longhua Hospital, Shanghai
University of TCM from Nov. 2014 to Dec 2016.Study population
Inclusion and exclusion criteria
We will recruit three main cohorts with confirmed
TCM constitutional types: Qi-Deficiency (n = 36),
Yin-Deficiency (n = 36) and Blood-Stasis (n = 36). All
subjects will be 20 to 35 years old and with normal
weight (18.5 kg/m2 ≤BMI <23.0 kg/m2). The detailed
inclusion and exclusion criteria are presented in Table 3.
All subjects will be surveyed beforehand for their
demographic characteristics and lifestyle patterns. The
screening will also include blood tests and the Constitution
in Chinese Medicine Questionnaire (CCMQ). After exclu-
sion of noneligible participants, the remaining subjects will
be assigned identification codes.
Table 3 Inclusion and exclusion criteria
Criteria
Inclusion - Aged 20 to 35
- 18.5 kg/m2 ≤body mass index (BMI) <23 kg/m2
- Traditional Chinese medicine (TCM)-constitutionally typed as one of the three major types
Exclusion - History of impaired fasting glucose or diabetes mellitus (past history of diabetes or fasting blood glucose at screening ≥100 mg/dl)
- History of liver disease (hepatitis, hepatic cirrhosis) or hepatic dysfunction (AST or ALT at screening ≥40 U/L)
- History of renal dysfunction (creatinine at screening ≥1.2 mg/dl)
- History of heart disease (heart failure, angina pectoris, myocardial infarction, arrhythmia)
- History of malignant tumor
- Having digestive disorders that can interfere with normal absorption of standard diet (gastritis, gastric ulcer, duodenitis, duodenal ulcer, etc.)
- Smoking during the recent 3 months
- Alcohol consumption three or more times a week during the recent 3 months
- Women who were pregnant, intended to become pregnant, or breast- feeding
- Medicated during the recent month for therapeutic or prophylactic purposes
- Participating in another clinical trial
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According to Classification and Determination of TCM
Constitution [4] released by the State Administration of
TCM and the constitution branch of the Chinese Medical
Association, two TCM specialists will adopt four TCM ex-
aminations (observation, listening and smelling, inquiring,
feeling the pulse and palpation) to totally assess the partic-
ipants and determine their constitutional types based on
physical, mental, physiological, and pathological attributes.
The TCM specialists involved are qualified traditional
Chinese medical doctors licensed by the Chinese govern-
ment, with 6 years of traditional Chinese medicine
training, minimum 3 years of training in TCM, and 9
years of further clinical experience. The constitutional
type will be confirmed only when both make concord-
ant decisions. The Constitution in Chinese Medicine
Questionnaire (CCMQ) [5-7] will be used to improve
objectiveness in decision-making.
Study procedures
Laboratory measurements and clinical assessment
A specific set of laboratory parameters will be measured for
every subject on the day of recruitment. These parameters
include blood count, electrolyte levels, renal and liver func-
tion parameters, blood lipid amounts. Furthermore, age,
gender, history of smoking, blood pressure, weight (kg), and
height (meters) will be obtained for all subjects. Standard
operating procedures have been defined for each clinical
examination, including the measurements of blood
pressure, height and weight [17].
Drug administration
Thirty-six healthy adult subjects in each cohort will be
randomly divided into three groups to receive threedifferent doses (low, 3.75 g; middle, 7.5 g; or high, 15 g).
Subjects will be randomly assigned following simple
randomization procedures (computerized random num-
bers) to each subgroup. Each dose of the Qishe pill (Shang-
hai Sundise Traditional Chinese Medicine Co., Ltd, China)
with the same lot number will be administered orally with
water (240 ml) after at least 10-hour fast. The low dose
(3.75 mg) was calculated according to the applicable regula-
tory guidance [18,19], using the No Observable Adverse Ef-
fect Level (NOAEL) in the most sensitive species (500 mg/
kg/day in Sprague–Dawley rats).
Subjects will be admitted to the study unit the evening
before drug administration. On the day of administra-
tion, single doses of the Qishe pill will be taken orally,
1h after a standardized meal. Regular standardized meals
will be provided 4 h after drug administration. Water is
allowed as desired, except for 1 hour before and 2 hours
after drug administration. The subjects will remain within
a supervised investigational unit for the subsequent 3-d
period for pharmacokinetic study and toxicity monitoring,
providing 3-day blood and urine samples. Vital signs and
clinical laboratory tests were done before and at 24 h after
dosing. Furthermore, they will be requested to return
to the study unit 4 d after drug administration for a
follow-up visit.
Sample collection
For the PK analysis and second-generation gene sequen-
cing, 5 ml blood samples will be collected into tubes
containing ammonium heparinate and centrifuged immedi-
ately at 4000 g for 10 min to obtain plasma samples. These
samples will be then transferred into polypropylene vials
and kept at −20°C until analysis. For the 7.5 and 15 g dose
groups, samples will be collected at dosing (time 0), and 15,
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2160 and 2880 min.
Furthermore, a comprehensive set of biomaterials
including EDTA-plasma (6 ml), serum (5 ml) and urine
(6 ml) will be collected and stored for future laboratory
analyses.
Safety assessments
Safety and tolerability will be assessed subjectively and
objectively. Subjective tolerability will be assessed by
questioning subjects about any adverse events (AE).
Objective tolerability will be assessed at scheduled
intervals by vital signs (body temperature, heart rate
and blood pressure), electrocardiograms (ECGs), the
examination of intravenous infusion sites, and identification
of adverse events (AEs). AE information will be collected
throughout the study, based on spontaneous volunteer
reports, interviews, clinical examinations and laboratory
tests (hematology, serum biochemistry, and urinalysis). The
investigators will assess all clinical AEs according to the
Medical Dictionary for Regular Activities criteria, in terms
of intensity (mild, moderate, or severe), duration, outcome
and relationship to the study drug. Those which are life
threatening, or lead to death, hospitalization, disability, or
medical intervention to prevent permanent impairment or
damage, will be considered as serious adverse events (SAE).
Each adverse event occurring to a subject has to be
recorded in the case-report form.
All study procedures are illustrated in Figure 1.
Instrumentation and conditions
The LC-MS/MS system consists of an ULTIMATE 3000
series UHPLC (Thermo Fisher Scientific, USA) coupled to
a TSQ QUANTUM ACCESS MAX Mass Spectrometer
(Thermo scientific, USA). Chromatographic separationFigure 1 Patient flowchart detailing the process, including screening,will be performed on a Waters Acquity UPLC BEH C18
column [100 mm*2.1 mm (i.d.); 1.7μm] (Waters, USA).
The standards and samples will be separated using a
mobile phase consisting of 0.1% formic acid in water
(solvent A) and methanol (solvent A). The gradient
elution program will be: 0–1 min, 20% A; 1–8 min,
20-100% A; 8–12 min, 100% A; and then back to 20%
A to recondition the column for 4 min. The flow rate
of the mobile phase will be 0.3 ml/min, with the column
temperature maintained at 40°C. ESI ionization performed
in the positive ion mode with a spray voltage of 3,000 V
and negative mode with a spray voltage of 2500 V will be
used. Sheath gas pressure and aux gas pressure will be set
at 35 psi and 5 psi, respectively. A capillary temperature of
350°C will be used. Quantification will be performed in
the multiple reaction monitoring (MRM) mode. The
optimized parameters, such as collision energy (CE) and
the tube lens for each compound, are summarized in
Table 4. Xcalibur (Ver. 2.1; Thermo scientific, USA) is
used to control the UHPLC/TSQ Quantum system, and
to acquire and process data.
Analytical assays
Plasma concentrations and urinary excretion rates of the
Qishe pill will be determined for up to 48 h using high-
performance liquid chromatography with fluorometric
detection according to a method used previously [20].
For sample preparation, plasma samples (100 ml) will be
mixed with 100 ml of internal standard (diphenhydramine,
purchased from the National Institutes for Food and Drug
Control, Beijing, China) working solution. The samples
will be extracted with 11:1 methanol–water (600 ml) by
vortex-mixing for 1 min at high speed and centrifugation
at 12,000xg for 10 min; 20 ml supernatant will be injected
in the LC/MS/MS system for analysis.allocation, and analysis.















CCS [M + H]+ 285.16 270.30 99 23 6.43
CCSG [M + H]+ 447.24 285.30 98 20 4.89
FAN [M + H]+ 623.44 381.40 130 40 4.89
PAL [M + H]+ 352.23 336.30 89 29 5.44
5-O-M [M + H]+ 453.27 291.30 108 22 6.01
ONO [M + H]+ 431.25 269.30 97 17 6.00
FOR [M + H]+ 269.20 197.30 97 34 7.32
AST-IV [M + Na]+ 807.53 627.40 221 49 8.69
BER [M + H]+ 336.19 320.28 94 30 5.38
*The compound abbreviations and their associated terms:
AST-IV: astragaloside IV; BER: berberine; CCS: calycosin; CCSG: calycosin-7-O-β-D- glucoside; FAN: fangchinoline; FOR: formononetin; ONO: ononin; PAL: palmatine;
5-O-M: 5-O-methylvisammioside.
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The pharmacokinetic parameters of the Qishe pill will
be estimated using noncompartmental methods. The ac-
tual blood sampling time will be used, and the maximum
plasma concentration (Cmax) and time to maximum
concentration (Tmax) will be recorded. The area under
the plasma concentration-time curve (AUC) will be
calculated using the linear trapezoidal rule. The elim-
ination rate constant (ke ) will be estimated from the
least-squares regression slope of the terminal plasma
concentration. The AUC from 0 to infinity (AUC0−∞)
will be calculated by (AUC0→t + Ct /ke ) (Ct is the last
plasma concentration measured). The elimination half-life
(t1/2) will be calculated as ln 2/ke. The distribution volume
(DF) will be calculated by Dose/AUC/ke.Deep phenotyping with genomics and functional
genomics approaches
Within pharmacokinetics of the Qishe pill, standardized
workflows for the omics characterization of biosamples will
be developed. Currently, genomic variants will be analyzed
for 144 subjects with the aid of the Human- CoreExome +
v1.1-Psych Array. For a subset of 144 subjects, whole blood
expression data will be generated using Illumina’s HT-12
bead chips. The findings will be complemented with
proteomic and metabolomic data using established work-
flows. Cytochrome P450 genes, such as CYP1A1, CYP1A2,
CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and
CYP3A5, among other, will be the targets.
Metabolomics provide comprehensive snapshots of the
metabolome of body fluids such as plasma or urine.
High-throughput metabolomic analyses mainly based on
1H nuclear magnetic resonance (NMR) spectroscopy,
a nondestructive analysis with minimal preparation
requirements, will be performed. NMR spectroscopy
provides robust and reproducible measurements. Massspectrometry (MS) with high analytical sensitivity will
be used for additional detailed studies.
Integrated analyses of these data for associations with
clinical and subclinical phenotypes will be performed using
the bioinformatics groups of the TCM constitutional type
classification.
Medical informatics and data management
The PopPK analysis will be performed with NONMEM
[21-23]. The plasma concentration-time profiles for all con-
stituents and derivatives of the Qishe pill will be described
by a base structural model using the subroutine ADVAN5
[24]. The PK structural model will be parameterized in
terms of apparent clearance and apparent distribution
volume (CL/F and V/F), where F is the unknown oral bio-
availability; the clearance and distribution volume are CLM
and VM, respectively. A Bayesian approach conditioned on
the population characteristics will be used to estimate spe-
cific individual parameters. First-order conditional estima-
tion methods (FOCE) and first-order conditional estimation
methods with interaction (FOCE-I) will be tested during
model development. The unexplained random variability in
individual values of the structural model parameters will be
described in the interindividual variability (IIV) model.
For the final model, a backward elimination process
will be employed to identify significant covariates. The
covariates in the full model will be excluded one by one.
The objective function value (OFV) will be compared
with that of the full model. A covariate will be retained
in the model when its elimination results in an increase
in the OFV of 7.88 (chi-square, P <0.005, df = 1). We
will select the model according to the reduction in the
OFV value, goodness-of-fit plots, reduction in the IIV of
structure model parameters, residual error, robust model
parameter estimation, and model stability. The architecture
and basic elements of the PopPK research is illustrated in
Figure 2.
Figure 2 Architecture and basic elements of the population pharmacokinetic (PopPK) research based on medical informatics and
data management.
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Cervical radiculopathy is a significant public health
problem worldwide, accounting for 60 to 70% of all cer-
vical spondylopathy cases; it is generally believed that
most symptoms can be cured or relieved by nonsurgical
treatments [25].
Previous evidence-based trials have reported that
analgesics and nerve-nutrition medicines have consider-
able effects on neck pain. Even though analgesics, such as
aspirin, seem to be relatively safe, gastrointestinal reactions
are often reported after their use [26]. Mecobalamin, a
neuropathy drug, which relieves neck pain by stimulating
the inhibition of nerve degeneration and improving
the excitability of nerve fibers [27], seems to be ineffective
when degeneration occurs.
The Qishe pill provides specific benefits for “Qi and
Blood”, terms in TCM, meaning that it can profit and
activate blood circulation. We have previously shown
that the Qishe pill reversibly inhibits the NF-κB pathway,
which might be an underlying mechanism behind its
anti-inflammatory potential in disc degeneration in vivoTable 5 Pharmacokinetic parameter after oral administration
(mean ± SD, n = 6)
Parameters SEA SEI FO
t1/2 (h) 22.72 ± 11.49 12.35 ± 10.3 51.
Cmax (ng/ml) 53.71 ± 16.14 136.51 ± 45.24 9.3
Tmax(h) 0.22 ± 0.07 0.31 ± 0.16 0.2
AUClast(h*ng/ml) 606.87 ± 161.89 851.3 ± 251.31 38.
AUCtot(h*ng/ml) 826.3 ± 229.51 900.76 ± 236.67 71.
MRT (h) 36.54 ± 15.27 16.58 ± 6.89 70.
CL (L/h/kg) 0.05 ± 0.01 0.02 ± 0.01 0.0
Vz (L/kg) 1.41 ± 0.67 0.41 ± 0.33 0.9[28]. Extensive investigations have confirmed that the
Qishe pill has several therapeutic features, inhibiting
platelet surface activity and platelet aggregation [29],
reducing the synthesis and release of local PGE [30],
decreasing malondialdehyde content in inflammatory
exudates [31], and inhibiting the IL-1beta-induced phos-
phorylation of extracellular signal-regulated kinases 1/2
and c-Jun N-terminal kinase [32]. These effects include
predictable pharmacokinetics (PK) and pharmacodynam-
ics (PD) behaviors; in addition, the Qishe pill suppresses
acute inflammatory reactions and pain events with
fewer gastrointestinal discomfort and rash. A simple
and sensitive method using ultra-high-performance liquid
chromatography–tandem mass spectrometry (UHPLC–
MS/MS) on a reverse-phase C18 column was developed
for the simultaneous determination of the 19 major
components of the Qishe pill [20]. This method was
successfully validated for the quantification of the 19
components in the Qishe pill products, and consti-
tutes a new standard in quality assessment of TCM
prescriptions containing multiple bioactive componentsof Qishe pill at a dose of 6.33 g•kg-1 to SD rats
R ONO 5-O-M AST-IV
24 ± 44.19 7.04 ± 3.7 42.79 ± 16.29 11.41 ± 12.51
9 ± 4.32 2.45 ± 1.51 0.14 ± 0.07 13.3 ± 5.42
2 ± 0.07 0.25 ± 0.00 0.25 ± 0.00 2.00 ± 2.25
1 ± 8.04 4.17 ± 1.53 1.13 ± 0.10 107.74 ± 65.65
57 ± 26.49 4.89 ± 1.65 2.31 ± 0.41 129.75 ± 61.01
4 ± 60.63 9.55 ± 4.04 65.96 ± 20.60 17.9 ± 17.38
2 ± 0.00 0.12 ± 0.05 0.16 ± 0.03 0.06 ± 0.07
8 ± 0.43 1.12 ± 0.83 9.38 ± 2.09 0.83 ± 0.94
Figure 3 Mean plasma concentration-time curves of seven components after oral administration of the Qishe pill at medium and high
dosages (n = 4).
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interactions between the Qishe pill ingredients and the
pharmacokinetics of flavonoids (calycosin and calycosin-
7-o–d-glycoside), alkaloids (tetrandrine, fangchinoline, mag-
noflorine and berberine hydrochloride), ferulic acid
and glycosides (astragaloside IV, astragalussaponin I
and III) have been reported [20,33-37]. Furthermore,
HPLC-TQ/MS was employed to detect the component
contents in the Qishe pill, whose partial pharmacokinetic
parameters are shown in Table 5.
In the pre-trial of limited size (n = 6), accordingly, a
UPLC-TQ/MS method for simultaneous determination of
plasma concentrations of 15 bio-active Qishe pill constitu-
ents was developed and validated. The results showed that
the method was selective, sensitive, precise, accurate, and
reliable for comparative quantification of ferulic acid,
calycosin, calycosin glycosides,calycosin-7-O-β-glucoside,
ononin, formononetin, astragaloside, tetrandrine, fang-
chinoline base, berberine, tetrahydroberberine, tetra-
hydropalmatine, sinomenine and magnolia base, in
human plasma samples. The mean plasma concentra-
tion–time profiles of the major bio-active components
determined after oral administration of Qishe pills are
illustrated in Figure 3.
According to the results of the pilot trial, further
research should be conducted with modified protocol
in dosage setting, requirements of sample collection
(diet specifications, blood-collection time window) and
sample processing.
Highlights
Diagnosis and treatment based on an overall analysis of
the illness and patient’s condition is the essence of the
TCM theory. Rational medication is dependent upon a
basic understanding of the way patients handle drugs
(pharmacokinetics) and their response to specific drug
effects (pharmacodynamics). Moreover, TCM constitu-
tional types in traditional Chinese recipes could signifi-
cantly influence the plasma concentration-time and their
pharmacokinetic parameters after oral administration
[38,39]. As data collection and OMICS analyses in PopPK
of the Qishe pill will be processed simultaneously,
research is focusing on the analyses of PK, OMICS and
laboratory data to generate new hypotheses for transla-
tional research such as individualized dose, individualized
scope of TCM and trial simulation.
The present study will establish three cohorts to detect
potential differences in pharmacokinetic characteristics
of the Qishe pill constituents in the three different TCM
constitutional types, to assess whether the rate and extent
of drug metabolism will be altered in Qi-deficiency or
Blood-stasis constitutional types. If the differences in
the Qishe Pill pharmacokinetics among the three
major constitutional groups were known, personalizedmedication strategies for people with the three major
constitutional types could be provided for the application
of TCM.
Trial status
Participant recruitment and prescreening began in
December 2014. Blank control serum samples have been
collected for standardization of the general methodology
and normal conditions.
Additional file
Additional file 1: Typical chromatograms of ultrahigh-performance
LC and tandem mass spectrometry (UHPLC-MS/MS) for (a) the
mixed standard substance and (b) a sample [32].
Abbreviations
AST-III: Astragaloside III; AST-IV: Astragaloside IV; AUC: area under the plasma
concentration–time curve; BER: Berberine; CA: Cholic acid; CCS: Calycosin;
CCSG: Calycosin-7-O-β-D- glucoside; CE: Collision energy; Cmax: Maximum
plasma concentration; DF: Distribution volume; CL/F: Apparent clearance;
CLM: Clearance; DAI: Daidzein; FAN: Fangchinoline; FOCE: First-order
conditional estimation methods; FOCE-I: First-order conditional estimation
methods with interaction; FOR: Formononetin; GA: Gallic acid; ke: Elimination
rate constant; MS: Mass spectrometry; MRM: Multiple reaction monitoring;
NMR: Nuclear magnetic resonance; OFV: Objective function value;
ONO: Ononin; PAL: Palmatine; PD: Pharmacodynamics; PK: Pharmacokinetics;
PopPK: Population pharmacokinetic; SEA: Senkyunolide A; SEI: Senkyunolide I;
SIN: Sinomenine; TCM: Traditional Chinese Medicine; Tmax: Time to maximum
concentration; UHPLC–MS/MS: Ultra-high-performance liquid
chromatography–tandem mass spectrometry; V/F: Apparent distribution
volume; VM: Distribution volume; 5-O-M: 5-O-methylvisammioside.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YLS participated in the study design, drafted the manuscript, and conducted
the clinical procedure and sample collection. TH participated in the study
design, revised the manuscript, and conducted the PK analysis and statistical
modeling. SFL and ZLZ participated in statistical design and conducted the
preliminary animal PK/PD analysis. MY and LY conducted the clinical
procedure and sample collection. QS formulated the Qishe pill and provided
academic advice in the Qishe pill administration. YJW, NZ and XJC gave
administrative support for the study. YJW is the general supervisor for this
research and participated in both the study design and critical revision of
the manuscript. All authors read and approved the final manuscript.
Authors’ information
Yue-li Sun and Ting Hou are co-first authors.
Acknowledgements
The National TCM clinical research base was supported by State Administration
of Traditional Chinese Medicine; Clinical Research Project of Traditional Chinese
Medicine was supported by the State Administration of Traditional Chinese
Medicine (201107004), “Three-year” project for promoting development of TCM
in Shanghai (2014-2016) supported by Shanghai Municipal Commission of
Health and Family Planning(ZY3-CCCX-3-2005); Selection and training project
for excellent technician of Shanghai University of Traditional Chinese Medicine;
“Shu Guang” project supported by Shanghai Municipal Education Commission;
Shanghai Education Development Foundation(10GG20); Longhua Medical
Team Project (LYTD-13); “Project Grant” supported by National Science Fund of
China (81373666); “Innovation Team” development projects supported by
Ministry of Education (IRT1270); “TCM Key projects” were supported by dept. of
Science and Technology in Shanghai (14401970401).
Sun et al. Trials  (2015) 16:64 Page 10 of 10Author details
1Longhua Hospital, Shanghai University of Traditional Chinese Medicine, No.
725, South Wanping Road, Shanghai 200032, P.R. China. 2Spine Institute,
Shanghai University of Traditional Chinese Medicine, No. 725, South Wanping
Road, Shanghai 200032, P.R. China. 3College of Traditional Chinese Herbal
Medicine, Shanghai University of Traditional Chinese Medicine, No. 1200
Cailun Road, Shanghai 201203, P.R. China. 4Zhe Jiang Biosia Pharmaceutical
Co., Ltd, No.1938 Xinqun Road, Pinghu City, Zhejiang Province, P.R. China.
Received: 6 November 2014 Accepted: 16 January 2015
References
1. Aker PD, Gross AR, Goldsmith CH, Peloso P. Conservative management of
mechanical neck pain: systematic overview and meta-analysis. BMJ.
1996;313(7068):1291–6.
2. Cui X, Trinh K, Wang YJ. Chinese herbal medicine for chronic neck pain due
to cervical degenerative disc disease. Cochrane Database Syst Rev.
2010; (1), CD006556
3. Wang Q. Classification of the nine basic TCM constitutional type and based
expression and diagnosis. J Beijing University Tradit Chin Med. 2005(04); 1-8.
4. Wang Q, Zhu YB. Epidemiological investigation of constitutional types of
Chinese medicine in general population: Base on 21,948 epidemiological
investigation data of nine provinces in China. ZhongHuaZhong Yi Yao
ZaZhi. 2009;24:7–12.
5. Wang Q, Zhu YB, Xue HS. Primary compiling of constitution in Chinese
Medicine questionnaire. ZhongGuo Lin Chuang Kang Fu. 2006;10:12–4.
6. Zhu YB, Wang Q, Xue HS, Origasa H. Preliminary assessment on
performance of constitution in Chinese medicine questionnaire. ZhongGuo
Lin Chuang Kang Fu. 2006;10:15–7.
7. Zhu YB, Wang Q, Origasa H. Evaluation on reliability and validity of the
constitution in Chinese medicine questionnaire (CCMQ). ZhongGuo Xing
Wei Yi XueKeXue. 2007;16:651–4.
8. Mei L, Zhang N, Wang YJ, Shi Q. Purification process research of major
compound in Qishe Pill as Astragalus. Acta Chin Med Pharmacol.
2006;34:14–6.
9. Zhang YQ, Liu XH, Zhang N, Liu M. Quality standard research of Qishe Pill.
Lishizhen Med Mater Med Res. 2008;19:977–9.
10. Liu M, Zhang N, Wang YJ, Zhang YQ, Zhou CJ. Technology research of
Qishe Pill, a new medicine for cervical spondylosis. Lishizhen Med Mater
Med Res. 2010;21:176–9.
11. Ge JR, Wang HM, Meng CX, Tong PJ. Effects of Qishe Pill, a compound
traditional Chinese herbal medicine, on cervical radiculopathy: a
randomized controlled trial for Phase III. Chin J New Drugs Clin. 2014;7:56–8.
12. Hsu H-Y. 1986 Oriental MateriaMedica. Long Beach, CA: Oriental Healing Arts
Institute; 1986.
13. Maurer K. U.S. Department of Health, Education, and Welfare. Basic data on
arthritis knee, hip and sacroiliac joints in adults ages 25–74 years:
United States, 1971–1975. Health Stat. 1979;11:1–31.
14. Mäkelä M, Heliövaara M, Sievers K, Impivaara O, Knekt P, Aromaa A.
Prevalence, determinants, and consequences of chronic neck pain in
Finland. Am J Epidemiol. 1991;134:1356–67.
15. Bovim G, Schrader H, Sand T. Neck pain in the general population. Spine
(Phila Pa 1976). 1994;19:1307–9.
16. Van der Donk J, Schouten JS, Passchier J, van Romunde LK, Valkenburg HA.
The associations of neck pain with radiological abnormalities of the cervical
spine and personality traits in a general population. J Rheumatol.
1991;18:1884–9.
17. Choo V. WHO reassesses appropriate body-mass index for Asian populations.
Lancet. 2002;360:235.
18. FDA/CDER. Guidance for industry estimating the maximum safe starting
dose in initial clinical trials for therapeutics in adult healthy volunteers;
July, 2005, http://www.fda.gov/downloads/drugs/guidance-
complianceregulatoryinformation/guidances/ucm078932.pdf.
19. EMEA. Strategies to identify and mitigate risks for first-in-human clinical
trialswith investigational medicinal products; Sept. 2009, http://www.ema.
europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/
WC500002988.pdf.
20. Zhang ZL, Li Q, Li QF, Du SM, Zhou YQ, Lv CM, et al. Simultaneous
determination of nineteen major components in Qishe Pill by ultra-high-
performance liquid chromatography–tandem mass spectrometry. ActaPharmaceutica Sinica B (2014); http://www.dx.doi.org/10.1016/j.
apsb.2014.05.003
21. Sheiner LB, Beal SL. Evaluation of methods for estimating population
pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical
pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8:553–71.
22. Sheiner BL, Beal SL. Evaluation of methods for estimating population
pharmacokinetic parameters. II. Biexponential model and experi- mental
pharmacokinetic data. J Pharmacokinet Biopharm. 1981;9:635–51.
23. Sheiner LB, Beal SL. Evaluation of methods for estimating population
pharmacokinetic parameters. III. Monoexponential model: routine clinical
pharmacokinetic data. J Pharmacokinet Biopharm. 1983;11:303–19.
24. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, et al. Population
pharmacokinetic analysis for risperidone using highly sparse sampling
measurements from the CATIE study. Br J Clin Pharmacol. 2008;66:629–39.
25. Qingmao Y. An 80-cases clinical observation of two conservative therapy of
traditional Chinese and western medicine to cervical spondylotic radiculopathy.
Chinese Foreign Health Abs. 2010;18:223–5.
26. Bin-Chia Wu D, Tsai YW, Wen YW. Bayesian cost-effectiveness analysis for
censored data-an application to antiplatelet therapy. J Med Econ.
2012;15:434–43.
27. Okada K, Tanaka H, Temporin K, Okamoto M, Kuroda Y, Moritomo H, et al.
Methylcobalamin increases Erk1/2 and Akt activities through the
methylation cycle and promotes nerve regeneration in a rat sciatic nerve
injury model. Exp Neurol. 2010;222:191–203.
28. Zhang WJ, Hufnagl P, Binder BR. Anti-inflammatory activity of astragaloside
IV is mediated by inhibition of NF-qB activation and adhesion molecule
expression. Thromb Haemost. 2003;90:904–14.
29. Chen SL, Jiang GH. Security and pharmacilogical effects of Szechuan Lovage
Rhizome extract. J Chengdu UnivTradit Chin Med. 2009;32:63–5.
30. Sun X, Yu XJ, Qiu MF. Clinical research progress of the pharmacology of
ovientvine. J China’s Integrated Tradit Chin Western Med Surg.
2005;11:363–4 [In Chinese].
31. Li X, Yu QH. Anti-inflammatory effects of Calculus BovisArtifactus: apilot
study. J Shengyang Pharm Univ. 2000;17:431–3.
32. Liang QQ, Zhang M, Zhou Q, Shi Q, Wang YJ. Muscone protects vertebral
end-plate degeneration by anti-inflammatory property. ClinOrthop Relat
Res. 2010;468:1600–10.
33. Du SM, Pan YF, Zhang N. Simultaneous determination with HPLC internal
standard method for nine kinds ingredients in Qishe Pill. Chin Tradit Pat
Med. 2012;7:1271–5.
34. Li Q, Du SM, Li QF, Zhang ZL, Zhang N. Effects of Qishe Pill on cervical
radiculopathy rat model with Qi-deficiency and Blood-stasis syndrome.
Pharmacol Clin. 2013;4:118–21.
35. Du SM, Li Q, Li QF, Zhang ZL, Zhang N. Invivo tissue distribution research of
ingredients in Qishe Pill. Chin J Exp Formulas Chin Med. 2013;19:171–6.
36. Wang D, Song Y, Li SL, Bian YY, Guan J, Li P. Simultaneous analysis of seven
astragalosides in Radix Astragali and related preparations by liquid
chromatography coupled with electrospray ionization time-of-flight mass
spectrometry. J Sep Sci. 2006;29:2012–22.
37. Yu QT, Qi LW, Li P, Yi L, Zhao J, Bi ZM. Determination of seventeen main
flavonoids and saponins in the medicinal plant Huang-qi (Radix Astragali)
by HPLC-DAD-ELSD. J Sep Sci. 2007;30:1292–9.
38. Huang X, Ren P, Wen AD, Wang LL, Zhang L, Gao F. Pharmacokinetics of
traditional Chinese syndrome and recipe: a hypothesis and its verification (I).
World J Gastroenterol. 2000;6:384–91.
39. Tian Y, Yang ZF, Li Y, Qiao Y, Yang J, Jia YY, et al. Pharmacokinetic
comparisons of hydroxysafflower yellow A in normal and blood stasis
syn- drome rats. J Ethnopharmacol. 2010;129:1–4.
